Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874043 | 0.86 | QDPR (0.64) | QDPRNPY5RALDH1A1MCHR1DRD4 | |
| SCHEMBL7287663 | 0.84 | QDPR (0.62) | QDPRNPY5RKDM4EBRD4ALDH1A1 | |
| SCHEMBL19658652 | 0.84 | QDPR (0.62) | QDPRALDH1A1MCHR1KCNH2 | |
| SCHEMBL10460507 | 0.84 | QDPR (0.62) | QDPRNPY5RMCHR1KCNH2 | |
| SCHEMBL3080099 | 0.84 | QDPR (0.62) | QDPRNPY5RKDM4EBRD4ALDH1A1 | |
| SCHEMBL15300836 | 0.84 | QDPR (0.62) | QDPRNPY5RKDM4EBRD4ALDH1A1 | |
| SCHEMBL1473424 | 0.84 | QDPR (0.61) | QDPRNPY5RKDM4EBRD4ALDH1A1 | |
| SCHEMBL17398139 | 0.84 | ESR2 (0.55) | QDPRESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL23250759 | 0.83 | QDPR (0.70) | QDPRNPY5RKDM4EBRD4ALDH1A1 | |
| SCHEMBL7230489 | 0.83 | QDPR (0.60) | QDPRNPY5RKDM4EBRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| EP-0528369-B1 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-11-24 | — | — | EP | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0528369-A2 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE4A | QDPR 314/4885ESR2 1682/4885NPY5R 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.